Nexgel (NXGL) Total Non-Current Liabilities (2018 - 2024)
Nexgel (NXGL) posted Total Non-Current Liabilities of $4.7 million for Q4 2024, down 11.1% on a QoQ basis from $5.3 million in Q3 2024, and up 8.62% year-over-year from $4.4 million in Q1 2024.
Nexgel (NXGL) Total Non-Current Liabilities (2018 - 2024) Analysis & Trends
Nexgel's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $4.7 million for Q4 2024.
- Quarterly Total Non-Current Liabilities rose 8.62% year-over-year to $4.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $4.7 million (up 8.62% YoY) and the FY2024 annual result came in at $4.7 million, up 8.62% from the prior year.
- Total Non-Current Liabilities was $4.7 million for Q4 2024 at Nexgel, down from $5.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.3 million in Q3 2024 and bottomed at $824000.0 in Q1 2021.
- A 5-year average of $2.9 million and a median of $2.0 million in 2021 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Total Non-Current Liabilities plunged 43.44% — and 2022, when it soared 139.32%.
- Nexgel's Total Non-Current Liabilities stood at $854000.0 in 2020, then soared by 135.36% to $2.0 million in 2021, then retreated by 5.42% to $1.9 million in 2022, then surged by 128.83% to $4.4 million in 2023, then rose by 8.62% to $4.7 million in 2024.
- Business Quant data shows NXGL's Total Non-Current Liabilities at $4.7 million in Q4 2024, $5.3 million in Q3 2024, and $4.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.14 Bn | 120.93 Bn | 1.96 Bn | 1.92 Bn |
| 2 | Becton Dickinson | 44.79 Bn | 43.98 Bn | 2.15 Bn | 48.37 Bn |
| 3 | Alcon | 32.93 Bn | 31.27 Bn | 1.53 Bn | 6.48 Bn |
| 4 | Medline | 32.91 Bn | 30.67 Bn | 1.84 Bn | 17.13 Bn |
| 5 | Resmed | 29.46 Bn | 27.80 Bn | 890.98 Mn | 941.16 Mn |
| 6 | West Pharmaceutical Services | 23.47 Bn | 23.04 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Solventum | 14.03 Bn | 13.47 Bn | 1.10 Bn | 8.65 Bn |
| 8 | Cooper Companies | 13.78 Bn | 13.64 Bn | 735.40 Mn | 4.24 Bn |
| 9 | Align Technology | 12.05 Bn | 10.99 Bn | 736.59 Mn | 2.06 Bn |
| 10 | Nexgel | 3.43 Mn | 1.63 Mn | 819,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.73 Mn |
| Sep 30, 2024 | 5.32 Mn |
| Jun 30, 2024 | 4.88 Mn |
| Mar 31, 2024 | 4.74 Mn |
| Dec 31, 2023 | 4.35 Mn |
| Sep 30, 2022 | 1.90 Mn |
| Jun 30, 2022 | 1.93 Mn |
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 2.01 Mn |
| Sep 30, 2021 | 2.05 Mn |
| Jun 30, 2021 | 2.07 Mn |
| Mar 31, 2021 | 824,000.00 |
| Dec 31, 2020 | 854,000.00 |
| Dec 31, 2019 | 1.51 Mn |
| Sep 30, 2019 | 1.44 Mn |
| Dec 31, 2018 | 407,000.00 |